Steven J Lemery

12PUBLICATIONS
88CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 05, 2026
FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal.

|Mar 06, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer.

Sandra J Casak, Yiming Zhang, Chi Song

|Jun 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer.

Sandra J Casak, Vaibhav Kumar, Chi Song

|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.

Michael J Fusco, Sandra J Casak, Sirisha L Mushti

|Dec 12, 2023
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.

Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco

|Sep 07, 2023
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.

Timil H Patel, Jamie R Brewer, Jiaxin Fan

Pageof 2

Frequent Collaborators

11 joint publications

Richard Pazdur

9 joint publications

Lola A Fashoyin-Aje

7 joint publications

Sandra J Casak

7 joint publications

Paul G Kluetz